Cost regulators for therapies funded by the NHS in England and Wales have added MSD’s Simponi (golimumab) to the list of treatments recommended for severe non-radiographic axial spondyloarthritis. More: NICE backs wider use of MSD’s Simponi Source: News
read moreEuropean regulators have expanded the scope of Vertex’ Orkambi to include children with cystic fibrosis aged six through 11 who have two copies of the F508del mutation. More: Vertex’ CF therapy Orkambi cleared for younger patients Source: News
read moreA combination therapy being developed by MSD and Eisai for kidney cancer has been awarded Breakthrough Designation in the US. More: US ‘breakthrough’ badge for MSD/Eisai cancer combo Source: News
read moreMSD has launched Zinplava in the UK, offering patients a novel therapeutic option for the prevention of Clostridium difficile recurrence. More: MSD launches Clostridium difficile antitoxin in the UK Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals